Trial Profile
A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 16 Sep 2016 Results of a pooled analysis assessing risk of bone fracture presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 16 Sep 2016 Results assessing safety data from 18 trials presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 01 Nov 2013 Results published in Diabetes Care.